Ultra-Precise Cancer Monitoring in 24 Hours

The ExoDiscovery Monitor® test delivers unprecedented sensitivity for monitoring cancer treatment response, detecting emerging resistance mutations, and tracking disease progression with 1-day turnaround time.
Contact Us
Contact Us
ExoDiscovery Monitor
Key benefits that transform cancer monitoring
Ultra-Sensitive Mutation Detection
ExoDiscovery Monitor analyzes RNA biomarkers within exosomes, achieving 10,000x greater sensitivity than conventional methods1. This revolutionary approach enables detection of emerging resistance mutations and treatment response assessment with unprecedented precision, allowing for timely therapy adjustments.
24-Hour Results
While conventional monitoring tests require 7-14 days for results, ExoDiscovery Monitor delivers complete mutation analysis in just 24 hours. This dramatic reduction in waiting time enables faster clinical decision-making, reduces patient anxiety, and allows for more timely therapy adjustments when needed most.
Longitudinal Treatment Monitoring
ExoDiscovery Monitor provides precise quantification of variant allele frequencies over time, enabling oncologists to track treatment response, detect early signs of resistance, and make data-driven decisions about therapy continuation or modification. The test complements imaging studies to provide a complete picture of disease status.
The industry fastest and most precise screening
ExoDiscovery Monitor transforms cancer detection with unprecedented speed and sensitivity1.
ExoDiscovery Monitor
Speed
24-hour turnaround time
Sensitivity
10,000x greater detection capability
Efficiency
No amplification required
Sample Size
Minimal 20μL plasma
Cost
Competitive test pricing
Conventional Methods
Speed
7-14 day waiting period
Sensitivity
Limited detection threshold
Efficiency
Complex PCR/NGS processing
Sample Size
10-20mL required
Cost
Higher testing expenses
VS
1. Accuracy is calculated as the proportion of true positive and true negative results among all tested samples. Data on file. Internal case-control, blind, retrospective study with n=101. Study results may not reflect real-world outcomes. Also see: Elizabeth Maria Clarissa, Sumit Kumar, Juhee Park, Mamata Karmacharya, In-Jae Oh, Mi-Hyun Kim, Jeong-Seon Ryu, and Yoon-Kyoung Cho. Digital Profiling of Tumor Extracellular Vesicle-Associated RNAs Directly from Unprocessed Blood Plasma. ACS Nano 2025 19 (5), 5526-5538. Sensitivity is defined as the percentage of actual positives correctly identified by the test. Specificity is defined as the percentage of actual negatives correctly identified by the test. Public data suggest conventional methods in comparable screening show <40% sensitivity in early-stage disease.
Discover the Future of Cancer Monitoring
ExoDiscovery's revolutionary technology provides unprecedented insights into cancer at the molecular level—enabling earlier detection and more precise treatment monitoring with 24-hour results.
Contact us to learn more about our technology or potential partnerships.
Add context to help us understand your area of interest
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.